Medicure Inc. · TSXV:MPH

Medicure — Investor Presentation (April 2015)

19 slides from Medicure's investor presentation, April 2015

  1. Slide 1: Investor Presentation

    Investor Presenta,on Albert D. Friesen, PhD Dawson Reimer Chair & CEO President & COO April 2015

  2. Slide 2: Disclaimer

    Disclaimer This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements

  3. Slide 3: Aggrastat Prescribing Information

    Aggrastat Prescribing Information Indication: AGGRASTAT is indicated to reduce the rate of thrombo,c cardiovascular events (combined endpoint of death, myocardial infarc,on, or refractory ischemia/repeat cardiac procedure) in pa,ents with non-­‐ST eleva,on acute coronary syndrome (NSTE-­‐ACS). Dosag

  4. Slide 4: Medicure Inc. Overview

    Medicure Inc. Overview $3.0 Aggrastat Quarterly Net Product Sales $2.5 (CDN Millions) $2.0 $1.5 $1.0 $0.5 Q1 Q3 Q4 Q3 Q2 Q4 Q1 Q2 $0.0 2013 2014 4

  5. Slide 5: Future Value Drivers

    Future Value Drivers • Additional regulatory studies • Penetrate Angiomax & Reopro Market • Established API Manufacture • Transdermal Aggrastat is in Development Tardoxal • New Product in Development for Motion Disorders * TARDOXAL is an experimental product that is not approved by the FDA 5 * AGGRA

  6. Slide 6: Aggrastat overview: launched by Merck in 1998, U.S. rights acquired 2006

    § Launched by Merck in 1998 § U.S. rights acquired by Medicure in 2006 § I.V. platelet inhibitor; binds the GP IIb/IIIa receptor § Indicated for Acute Coronary Syndrome (ACS) § 41% reduction in death and MI in high-risk patients* § Patent expiration: June 2023 New FDA Approved High Bolus Dosin

  7. Slide 7: Competitive Positioning of Aggrastat

    Competitive Positioning of Aggrastat 7

  8. Slide 8: Aggrastat Growth Strategy

    Aggrastat Growth Strategy Sales & Marketing Continue to expand and educate sales staff Label Change: FDA Label for HDB to increase market penetration – October 11, 2013 (increased market share rolling 12 month vs prior 12 month) Clinical Activity: Studies increase knowledge and drive physician inter

  9. Slide 9: New US Hospitals Using Aggrastat

    New US Hospitals Using Aggrastat 9

  10. Slide 10: New Commercial Model Weekly Bag Demand

    New Commercial Model Weekly Bag Demand 10

  11. Slide 11: GPI Acquisition Costs

    $3,500 GPI Acquisition Costs $3,000 Aggrastat: 25 µg/kg § US healthcare system is bolus + 0.15 µg/kg/min financially stressed $2,500 Integrilin: 2x180 µg/kg bolus + 2.0 µg/kg/min § Integrilin often one of the largest $2,000 Reopro: 0.25 mg/kg pharmacy line items $3,126.12 bolus + 0.125 µg/kg/min $

  12. Slide 12: Aggrastat Price vs. Angiomax

    Aggrastat Price vs. Angiomax $2,000 $1,781.60 Angiomax § 2001 – 2013 Angiomax replaced > 1/2 of GPIs in US $1,500 § Aggrastat short infusion is $890.80 alternative to Angiomax Angiomax $1,000 § Typical hospital savings: $100,000 - $1,500,000 / year $500 $247.29 $247.29 Aggrastat Aggrastat $0 Bolu

  13. Slide 13: SAVI PCI Study Design

    SAVI PCI Study Design Total ∼675 patients undergoing PCI (March Enrollment Update: ∼2/3 Complete) Choice of Oral Anti-Platelet(s) ASA and clopidogrel or prasugrel or ticagrelor I.V. Anti-Thrombin Unfractionated Heparin 50 U/kg 1:1:1 randomization Open-label Tirofiban HDB (short) Eptifibatide Tirofib

  14. Slide 14: SAVI PCI Clinical Study

    SAVI PCI Clinical Study § Aggrastat is the only GPI Approved with Short Infusion § Benefit of Short Infusion: • Poten,al for reduced bleeding while s,ll maintaining efficacy • Fits beier with contemporary medicine & facilitates outpa,ent PCI 0.5 hrs 1 - 2 hrs 12 - 24 hrs PCI SAVI PCI Tradi/onal Treat

  15. Slide 15: Apicore Transaction

    Apicore Transaction Deal Features: 1. Medicure receives fixed price options to buy 100% ownership until July 2017 2. Medicure receives 6.1% equity (5.3% fully diluted) Press Release: July 3, 2014 3. $22.5 Million share purchase & debt financing of Apicore structured by Medicure Medicure Acquires Min

  16. Slide 16: Apicore Background

    Apicore Background § API Manufacturer & ANDA Developer • Complex synthetic chemistry • Early & “first to file” generics • Secure, high quality production Somerset, New Jersey § History: • Opened US facility in 2004 • First FDA approval in 2006 (Granisetron HCl, post-chemo anti-nausea) • Filed DMF

  17. Slide 17: Business Vision

    Business Vision Aggrastat Quarterly Net Product Sales (CDN Millions) $3.0 $2.5 § To build a large, stable, specialty pharmaceutical company $2.0 § To further expand Aggrastat revenue $1.5 § To expand revenue with new commercial products $1.0 § To diversify company value with new products and bus

  18. Slide 18: Thank you.

    Thank you. Contact a Product Specialist Investor Rela/ons 1.800.509.0544 [email protected] 1.888.435.2220 (Ext. 231) For More Informa/on Analyst Coverage www.medicure.com www.aggrastat.com Andre Uddin Mackie Research 18

  19. Slide 19: Aggrastat Prescribing Information

    Aggrastat Prescribing Information Indication: AGGRASTAT is indicated to reduce the rate of thrombo,c cardiovascular events (combined endpoint of death, myocardial infarc,on, or refractory ischemia/repeat cardiac procedure) in pa,ents with non-­‐ST eleva,on acute coronary syndrome (NSTE-­‐ACS). Dosag

Medicure — Investor Presentation (April 2015) on 6ix